649 related articles for article (PubMed ID: 24267807)
1. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.
Jabor B; Choi H; Ruel I; Hafiane A; Mourad W; Genest J
Can J Cardiol; 2013 Dec; 29(12):1679-86. PubMed ID: 24267807
[TBL] [Abstract][Full Text] [Related]
2. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
Xu RX; Zhang Y; Li XL; Li S; Guo YL; Dong Q; Liu G; Li JJ
Clin Chim Acta; 2015 Jun; 446():195-200. PubMed ID: 25934512
[TBL] [Abstract][Full Text] [Related]
3. Association between the serum lipoprotein-associated phospholipase A
Dong L; Tong J; Fan S
Cardiovasc J Afr; 2023 Nov-Dec 23; 34(5):273-277. PubMed ID: 36637451
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China.
Huang Y; Wu Y; Yang Y; Li W; Lu J; Hu Y
Sci Rep; 2017 Nov; 7(1):16092. PubMed ID: 29170433
[TBL] [Abstract][Full Text] [Related]
5. Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography.
Dohi T; Miyauchi K; Ohkawa R; Nakamura K; Thuboi S; Ogita M; Miyazaki T; Nishino A; Yokoyama K; Kurata T; Yatomi Y; Daida H
Ann Clin Biochem; 2012 Nov; 49(Pt 6):527-33. PubMed ID: 22933444
[TBL] [Abstract][Full Text] [Related]
6. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Charniot JC; Khani-Bittar R; Albertini JP; Giral P; Cherfils C; Cosson C; Guillerm E; Leprince P; Gandjbakhch I; Bonnefont-Rousselot D
Int J Cardiol; 2013 Sep; 168(1):132-8. PubMed ID: 23103135
[TBL] [Abstract][Full Text] [Related]
7. Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort.
Li N; Li S; Yu C; Gu S
Postgrad Med; 2010 Jul; 122(4):200-5. PubMed ID: 20675983
[TBL] [Abstract][Full Text] [Related]
8. Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers.
Ostadal P; Vondrakova D; Kruger A; Janotka M; Psotova H; Prucha M
Lipids Health Dis; 2012 Nov; 11():153. PubMed ID: 23140470
[TBL] [Abstract][Full Text] [Related]
9. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
[TBL] [Abstract][Full Text] [Related]
11. Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome.
Dohi T; Miyauchi K; Okazaki S; Yokoyama T; Ohkawa R; Nakamura K; Yanagisawa N; Tsuboi S; Ogita M; Yokoyama K; Kurata T; Yatomi Y; Daida H
Atherosclerosis; 2011 Dec; 219(2):907-12. PubMed ID: 22024276
[TBL] [Abstract][Full Text] [Related]
12. Is lipoprotein-associated phospholipase A2 activity correlated with fibrous-cap thickness and plaque volume in patients with acute coronary syndrome?
Gu X; Hou J; Yang S; Yu H; Tian J; Liu F; Li N; Yu B; Jang IK
Coron Artery Dis; 2014 Jan; 25(1):10-5. PubMed ID: 24089018
[TBL] [Abstract][Full Text] [Related]
13. Plasma lipoprotein-associated phospholipase A2 mass is elevated in STEMI compared to non-STEMI patients but does not discriminate between myocardial infarction and non-cardiac chest pain.
Dullaart RP; van Pelt LJ; Kwakernaak AJ; Dikkeschei BD; van der Horst IC; Tio RA
Clin Chim Acta; 2013 Sep; 424():136-40. PubMed ID: 23756128
[TBL] [Abstract][Full Text] [Related]
14. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
15. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Rosenson RS
Am Heart J; 2008 Mar; 155(3):499.e9-16. PubMed ID: 18294485
[TBL] [Abstract][Full Text] [Related]
16. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans.
Lavi S; McConnell JP; Rihal CS; Prasad A; Mathew V; Lerman LO; Lerman A
Circulation; 2007 May; 115(21):2715-21. PubMed ID: 17502572
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
Li J; Zhou Z; Niu X; Li H
Clin Lab; 2020 May; 66(5):. PubMed ID: 32390386
[TBL] [Abstract][Full Text] [Related]
19. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
[TBL] [Abstract][Full Text] [Related]
20. Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution.
Sánchez-Quesada JL; Vinagre I; de Juan-Franco E; Sánchez-Hernández J; Blanco-Vaca F; Ordóñez-Llanos J; Pérez A
Am J Cardiol; 2012 Jul; 110(1):67-71. PubMed ID: 22481012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
